Media Articles Related to Zymar (Gatifloxacin Ophthalmic)
Source: MedicineNet Relapsing Polychondritis Specialty [2013.12.06]
Title: Pinkeye (Conjunctivitis)
Category: Symptoms and Signs
Created: 10/13/2003 12:00:00 AM
Last Editorial Review: 12/6/2013 12:00:00 AM
Short course immunotherapy effective in reducing ragweed pollen allergy
Source: Allergy News From Medical News Today [2014.01.28]
Allergy Therapeutics, has announced that a paper entitled "Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen" is now available in the print edition of The Journal of Allergy and Clinical Immunology, the peer reviewed, high impact journal. The trial was conducted between May 2005 - Jan 2006.
Published Studies Related to Zymar (Gatifloxacin Ophthalmic)
Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. [2011.09]
AIM: To compare the aqueous humour penetration of moxifloxacin 0.5% and gatifloxacin 0.3% eye drops administered in two different dosing regimens during phacoemulsification surgery... CONCLUSION: Moxifloxacin, given in the same dosage, penetrated the aqueous humour better then gatifloxacin during cataract surgery. The penetration of both antibiotics increased significantly when the dosage of the agent was doubled.
A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. [2011.08]
CONCLUSIONS: We conclude that in Vietnam, where nalidixic acid resistant Shigellae are highly prevalent, ciprofloxacin and gatifloxacin are similarly effective for the treatment of acute shigellosis.
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06]
PURPOSE: To determine the concentrations of besifloxacin, moxifloxacin, and gatifloxacin in human aqueous humor after topical instillation of commercially available besifloxacin ophthalmic suspension 0.6%, moxifloxacin ophthalmic solution 0.5%, and gatifloxacin ophthalmic solution 0.3%, and to assess these concentrations relative to the minimum inhibitory concentration for 90% of strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of postoperative endophthalmitis. SETTING: Six clinical sites, United States. DESIGN: Randomized open-label controlled clinical trial... CONCLUSIONS: Based on the aqueous humor drug concentrations measured in this study, it is unlikely that any of the fluoroquinolones tested would be therapeutically effective in the aqueous humor against the most frequently identified drug-resistant staphylococcal isolates from recent cases of postoperative endophthalmitis. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. [2011.06]
BACKGROUND: We aimed to investigate whether gatifloxacin, a new generation and affordable fluoroquinolone, is better than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults... INTERPRETATION: Although no more efficacious than chloramphenicol, gatifloxacin should be the preferred treatment for enteric fever in developing countries because of its shorter treatment duration and fewer adverse events. FUNDING: Wellcome Trust. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. [2009.08]
PURPOSE: We sought to assess the efficacy of 3-day topical gatifloxacin use in combination with povidone-iodine (PVI) versus PVI alone in eliminating conjunctival bacterial flora in patients scheduled to undergo intravitreal (IVT) injection. DESIGN: Prospective, randomized single-blind clinical trial. PARTICIPANTS: We included 129 patients scheduled to undergo 273 IVT injections at California Vitreoretinal Center at Stanford University... CONCLUSIONS: Although 3-day topical gatifloxacin use is effective in reducing the frequency of conjunctival bacterial growth relative to untreated eyes, antibiotic use confers no additional benefit in combination with PVI than eyes receiving PVI alone. This supports that topical PVI is an effective preinjection monotherapy for infection prophylaxis in the setting of IVT injections.
Clinical Trials Related to Zymar (Gatifloxacin Ophthalmic)
Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision [Not yet recruiting]
The purpose of this study is to determine whether there is a difference in corneal
epithelial healing rate and/or toxicity following pterygium excision, between eyes treated
post-operatively by moxifloxacin(VIGAMOX)versus gatifloxacin (ZYMAR).
Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour Application [Recruiting]
Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the
risk of infection. Previous studies have suggested that antibiotics containing a
preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox).
The purpose of this research is to compare how quickly to the two commonly prescribed
antibiotics eliminate bacteria from the eye surface.
Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose [Active, not recruiting]
The purpose of this study is to analyze the effect of Zymar and Vigamox on ocular surface
bacteria. We believe that Zymar will eradicate more ocular surface bacteria than Vigamox.
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever [Recruiting]
The investigators aim to compare two antibiotic treatments for enteric (typhoid) fever.
Three hundred patients at Patan Hospital will be enrolled in the study. Patients will be
assigned to one of the two treatments by chance and followed for 6 months. The two
treatment groups will be compared to see which treatment is more likely to make the patient
Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery [Suspended]
Postoperative endophthalmitis, a possible severe complication of cataract surgery, is an
infection of the anterior chamber of the eye caused by bacterial contamination and
colonization through surgical incisions. Bacteria are thought to originate mainly from the
patient’s skin and studies show that bacteria are commonly found in the anterior chamber
following surgery. However, innate immune defences are usually able to control and eliminate
bacterial growth before postoperative endophthalmitis occurs. Also, due to the low incidence
of postoperative endophthalmitis, it is difficult to accurately evaluate preventative
methods. This study will examine the efficacy of topical preoperative administration of
gatifloxacin (a new fourth generation fluoroquinolone antibiotic) on reduction of bacterial
contamination of the anterior chamber following cataract surgery. If the antibiotic is shown
to lower bacteria count in cultures from anterior chamber fluid, it has the potential to
lower the incidence of postoperative endophthalmitis.
Patients undergoing cataract surgery will be notified and asked to participate in the study
by the physician in advance of the surgery, provided they do not possess any exclusion
criteria. The participants will be randomly split into two groups; one group will receive
topical application of gatifloxacin prior to surgery, while the other group will receive no
eye drops. During surgery, a small sample of anterior chamber fluid will be removed from the
eye and cultured in both broth and enrichment media for all subjects. Bacterial growth, i. e.,
colony forming units (CFUs), will be used as an indicator of the bacterial contamination of
Reports of Suspected Zymar (Gatifloxacin Ophthalmic) Side Effects
Toxic Anterior Segment Syndrome (7),
Chest Discomfort (1),
Rash Papular (1),